Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer)
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 115
- Referral date:
- 01 December 2007
- Topic area
- Cancer
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
- 2nd appraisal committee meeting:
- TBC
Project Team
- Communications manager:
- Sarita Tamber
- Executive Lead:
- Gillian Leng
- Project manager:
- Bijal Joshi
- Technical Lead:
- Scott Goulden
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 August 2009 |
Further to the Scoping Workshop, lapatinib for the first-line treatment of metastatic hormone-sensitive breast cancer has been temporarily suspended. Following discussion of the comments received during the scoping exercises/workshop, we are liaising with the Department of Health for confirmation that lapatinib is appraised alongside trastuzumab, in a Multiple Technology Appraisal. When further details are available, the website will be updated. |
For further information on our processes and methods, please see our CHTE processes and methods manual